weight loss

Ozempic syringe pen and measuring tape on blue background
Biotech

Novo plots ph. 3 trials for next-gen obesity asset amycretin

The Danish pharma is moving forward with both subcutaneous and oral versions of amycretin, a GLP-1 and amylin receptor agonist.
Gabrielle Masson Jun 13, 2025 10:35am
bumpy road rough bad path

BioAge inks option agreement for Chinese biotech's obesity asset

Jun 3, 2025 2:06pm
arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am
MA strategy deal block push come together form

Mira seeks to buy Skny for obesity, smoking cessation asset

Mar 24, 2025 10:08am
boat cutting through water

Amgen’s late-stage obesity trials expected to read out in ‘27

Mar 5, 2025 1:58pm
obesity overweight weight loss weigh

Kallyope links oral obesity combo to 3% weight loss at Week 13

Feb 27, 2025 10:17am